CapVest-backed Curium agrees to buy Lantheus for up to $8bn

CapVest Partners-backed Curium has agreed to buy Lantheus, a US radiopharmaceutical company, in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed company private. Curium US will buy all outstanding Lantheus shares for $102.50 each at closing.

Lantheus shareholders will also receive non-transferable contingent value rights worth up to an additional $12.00 per share if certain commercial milestones for its product portfolio are met by 2030, bringing the potential total to $114.50 per share. The price is a 38% premium to Lantheus' 60-day volume-weighted average price and 21% above its closing price on 21 May 2026, the last trading day before media reports of a potential sale. The board has unanimously approved the proposed transaction.

Lantheus executive chair and CEO Mary Anne Heino said the deal validates the company's work in radiopharmaceuticals. Curium CEO Renaud Dehareng said Lantheus adds US commercial infrastructure, a F18-based prostate diagnostics franchise and entry into US neurology and echocardiography diagnostics. The combined company would operate in oncology, neurology and cardiology across more than 70 countries, subject to approval and closing.